Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewMNI 137
说明： Selective negative allosteric modulator of group II mGlu receptors
化学名： 4-(8-Bromo-2,3-dihydro-2-oxo-1H-1,5-benzodiazepin-4-yl)-2-pyridinecarbonitrile
纯度： ≥98% (HPLC)
生物活性 for MNI 137
MNI 137 is a selective negative allosteric modulator of group II mGlu receptors (IC50 values are 8.3 and 12.6 nM for human and rat mGlu2 inhibition of glutamate-induced calcium mobilization). Displays no activity at mGlu1, mGlu4, mGlu5 or mGlu8 receptors in a calcium mobilization assay.
化合物库 for MNI 137
MNI 137 is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。
技术数据 for MNI 137
| 分子量 | 341.16 |
| 公式 | C15H9BrN4O |
| 储存 | Store at +4°C |
| 纯度 | ≥98% (HPLC) |
| CAS Number | 946619-21-2 |
| PubChem ID | 25210562 |
| InChI Key | KMKZCMKOSAKVGY-UHFFFAOYSA-N |
| Smiles | O=C1CC(C3=CC=NC(C#N)=C3)=NC2=C(C=C(Br)C=C2)N1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for MNI 137
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| DMSO | 17.06 | 50 |
制备储备液 for MNI 137
以下数据基于产品分子量 341.16。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.5 mM | 5.86 mL | 29.31 mL | 58.62 mL |
| 2.5 mM | 1.17 mL | 5.86 mL | 11.72 mL |
| 5 mM | 0.59 mL | 2.93 mL | 5.86 mL |
| 25 mM | 0.12 mL | 0.59 mL | 1.17 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for MNI 137
参考文献 for MNI 137
参考文献是支持产品生物活性的出版物。
Hemstapat et al (2007) A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. J.Pharmacol.Exp.Ther. 322 254 PMID: 17416742
If you know of a relevant reference for MNI 137, please let us know.
关键词: MNI 137, MNI 137 supplier, MNI137, glutamate, mGluRs, receptors, group, II, negative, allosteric, modulators, NAMs, selective, Glutamate, (Metabotropic), Group, Receptors, 4388, Tocris Bioscience
MNI 137 的评论
目前没有该产品的评论。 Be the first to review MNI 137 and earn rewards!
Have you used MNI 137?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.